What question did this study set out to answer?

This research aims to investigate the effectiveness of MCC950-loaded M12-liposome nanoparticles in targeting the NLRP3 inflammasome in muscle atrophy due to sepsis.

April 17, 2026Open Access

MCC950‐Loaded M12‐Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis‐Induced Muscle Atrophy

Key Points

This research aims to investigate the effectiveness of MCC950-loaded M12-liposome nanoparticles in targeting the NLRP3 inflammasome in muscle atrophy due to sepsis.
Developed MCC950-loaded M12-liposome nanoparticles for targeted delivery.
Administered nanoparticles to skeletal muscle.
Assessed inhibition of NLRP3 inflammasome activation and muscle atrophy.
M12-liposome@MCC950 nanoparticles significantly inhibited NLRP3 inflammasome activity.
Observed relief from muscle atrophy in sepsis models.
Reduced systemic toxicity compared to traditional delivery methods.

Abstract

M12-Liposome@MCC950 NPs provide a targeted and sustained-release strategy for delivering MCC950 to skeletal muscle, effectively inhibiting NLRP3 inflammasome activation and alleviating SIM. This approach enhances therapeutic efficacy while mitigating systemic toxicity, highlighting the potential of nanomedicine-based interventions for treating inflammation-related myopathies.

MCC950‐Loaded M12‐Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis‐Induced Muscle Atrophy

Key Points

Abstract

Cite This Study